BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on ...

PRNewswire/ -- nference, a company dedicated to transforming healthcare by making biomedical data computable, today announced a collaboration with BeiGene, Ltd, a global oncology company that intends ...

In a statistical analysis, Brukinsa resulted in fewer cases of disease progression or death and resulted in lower overall healthcare costs than Imbruvica in patients with chronic lymphocytic leukemia.

BeiGene has decided to end the clinical development program for ociperlimab (BGB-A1217) as a treatment for lung cancer.

--Up 12.72% at today's intraday high; largest intraday percent increase since March 13, 2024, when it rose as much as 12.85% Though they varied in length and severity, the market always recovered and ...

Limited’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Analysts have set 12-month price targets for BeiGene, revealing an average target of $330.25, a high estimate of $348.00, and ...

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of non-small cell lung cancer ...

Doha, Qatar: Ebn Sina Medical, a subsidiary of Aamal Company Q.P.S.C. and a leading supplier of pharmaceutical, hospital, and ...

Shares off nearly all of the 100 largest public companies in Massachusetts were up Wednesday afternoon following a social ...

Chinese stocks whipsawed as the country’s trade war with the US worsened, after President Donald Trump promised to push ahead with even bigger tariffs. The Hang Seng China Enterprises Index tumbled as ...